A Multi-centre, Prospective, Single-arm, Non-interventional Study Describing the Use of the Dose Check App in People Living With Type 2 Diabetes Mellitus and Treated With IDegLira in a Real-world Setting in Italy

This study will look at how a mobile based app called 'Dose Check' used along with Xultophy® helps the treatment in participants with type 2 diabetes mellitus (T2DM). Participants will get Xultophy® as prescribed by study doctor or will continue already prescribed treatment with Xultophy®. Participants will also be prescribed to use Dose Check app by study doctor. Participants will be asked to install the Dose Check app in their mobile phone, which will be supported with the correct dose of Xultophy®. The study will last for about 6 to 8 months.

开始日期2024-11-07

申办/合作机构

Novo Nordisk A/S

ChiCTR2400086382

/ Suspended临床4期IIT

Safety and efficacy of GLP-1RA combined with Banxia Xiexin Decoction in the treatment of type 2 diabetes

开始日期2024-07-15

申办/合作机构-

NCT06408532

/ Not yet recruiting临床4期IIT

The Evaluation of the Efficacy and Safety of Switching to Once-daily IDegLira in Patients With Type 2 Diabetes Receiving Premixed Insulin Therapy, a Multi-center, Randomized Control Trial

The study aims to evaluate the efficacy and safety of IDegLira in type 2 diabetes who have failed premixed insulin therapy. The study plans to enroll 256 participants with inadequate glycemic control despite twice-daily subcutaneous injections of premixed insulin and metformin. Participants will be randomly assigned to either the premixed insulin dose optimization group (control group) or IDegLira once daily group, and the difference in change in glycated hemoglobin levels from baseline to 16 weeks of treatment will be assessed between the two groups.

开始日期2024-04-30

申办/合作机构

北京大学人民医院

100 项与德谷胰岛素/利拉鲁肽相关的临床结果

登录后查看更多信息

100 项与德谷胰岛素/利拉鲁肽相关的转化医学

登录后查看更多信息

100 项与德谷胰岛素/利拉鲁肽相关的专利（医药）

登录后查看更多信息

774

项与德谷胰岛素/利拉鲁肽相关的文献（医药）

2025-12-01·Current Neurology and Neuroscience Reports

Special Considerations in the Treatment of Idiopathic Intracranial Hypertension

Review

作者: Friedman, Deborah I

PURPOSE OF REVIEW:

To review the management of Idiopathic Intracranial Hypertension (IIH) with co-existing conditions affecting therapy: obesity, sulfa allergy, nephrolithiasis, and pregnancy.

RECENT FINDINGS:

The IIH-WT trial showed that bariatric surgery is currently the most effective method for obese patients with IIH to lose weight, leading to normalization of CSF pressure in many cases. Allergy to sulfonamide antibiotics does not preclude the use of acetazolamide; rather, penicillin allergy or multiple drug allergies are the strongest predictor of a hypersensitivity reaction. Carbonic anhydrase inhibitors should be avoided in individuals with a personal history of nephrolithiasis; the risk of renal stones increases with concomitant use of other medications with the potential for nephrolithiasis. Glucagon-like peptide-1 receptor antagonists (GLP-1RA) are promising non-surgical weight loss options although preliminary studies have not demonstrated considerable impact on papilledema, headache or vision. Women with IIH have high rates of pregnancy complications partly related to obesity. Recommendations for weight gain or loss during gestation are controversial. Recent studies show better outcomes in obese women who maintain or lose weight while pregnant including gestational diabetes, pre-eclampsia and emergency caesarian section. Progress continues in the search for the cause and best treatments for IIH. Larger multicenter trials of GLP-1RA are needed to determine their efficacy.

2025-04-01·Clinical Gastroenterology and Hepatology

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-Analysis

Review

作者: Samanta, Jayanta ; Dhar, Jahnvi ; Dinis-Ribeiro, Mario ; Hassan, Cesare ; Facciorusso, Antonio ; Crinò, Stefano Francesco ; Gkolfakis, Paraskevas ; Triantafyllou, Konstantinos ; Fuccio, Lorenzo ; Maida, Marcello ; Boskoski, Ivo ; Ramai, Daryl ; Chandan, Saurabh ; Anderloni, Andrea ; Arvanitakis, Marianna

BACKGROUND AND AIMS:

Limited evidence exists regarding the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on upper endoscopy. Therefore, a meta-analysis was conducted to comprehensively review the available evidence on this subject.

METHODS:

A systematic bibliographic search was carried out until May 2024. Pooled estimates were analyzed using a random-effects model, with results presented as odds ratio (OR) and 95% confidence interval (CI). The primary outcome assessed was the rate of retained gastric content (RGC), while secondary outcomes included rates of aborted and repeated procedures, adverse event rate, and rates of aspiration.

RESULTS:

This analysis included 13 studies involving a total of 84,065 patients. Patients receiving GLP-1RA therapy exhibited significantly higher rates of RGC (OR, 5.56; 95% CI, 3.35 to 9.23), a trend that was consistent among patients with diabetes (OR, 2.60; 95% CI, 2.23 to 3.02). Adjusted analysis, accounting for variables such as sex, age, body mass index, diabetes, and other therapies, confirmed the elevated rates of RGC in the GLP-1RA user group (adjusted OR, 4.20; 95% CI, 3.42 to 5.15). Furthermore, rates of aborted and repeated procedures were higher in the GLP-1RA user group (OR, 5.13; 95% CI, 3.01 to 8.75; and OR, 2.19; 95% CI, 1.43 to 3.35; respectively). However, no significant differences were found in AE and aspiration rates between the 2 groups (OR, 4.04; 95% CI, 0.63 to 26.03; and OR, 1.75; 95% CI, 0.64 to 4.77; respectively).

CONCLUSION:

Use of GLP-1RAs is associated with increased retention of gastric contents and more frequent aborted procedures during upper endoscopy. However, the adverse event and aspiration rates do not seem different; therefore, adjusting fasting time instead of routinely withholding GLP-1RAs could be reasonable in these patients.

2025-03-16·POSTGRADUATE MEDICAL JOURNAL

Effects of new hypoglycemic drugs on patients with heart failure: a systematic review and network meta-analysis

Review

作者: Chen, Jun ; Song, Ruirui ; Gao, Hongmei ; Liu, Fang ; Sun, Songtao ; Shi, Xiaojing

Abstract:

Background:

Currently, there is no relevant study comparing sodium-dependent glucose transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and dipeptidyl peptidase inhibitor (DPP4i) head to head to evaluate their comprehensive impact on heart failure patients.

Methods:

We conducted a comprehensive literature search across multiple databases. Utilizing the risk of bias tool from the Cochrane Collaboration, the methodological quality of included studies was critically assessed and potential publication bias was examined via funnel plots.

Results:

All results are presented as mean difference; 95% confidence interval (MD; 95% CI). The network meta-analysis indicated that in regards to left ventricular function, there is a big difference in the left ventricular ejection fraction (LVEF) of Empagliflozin 25 mg (13.64; 0.26, 27.01) compared to Canagliflozin 100 mg; and significant differences in the left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) of Dapagliflozin 10 mg (−0.76; −1.27, −0.25 and −0.95; −1.86, −0.05), Vildagliptin 50 mg (−1.05; −1.47, −0.63 and −1.12; −2.19, −0.05), and Sitagliptin 100 mg (−1.34; −2.31, −0.38 and −1.89; −3.50, −0.27) compared to Empagliflozin 10 mg. In terms of the quality of life, there are significant differences in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) and the Quality of life score of Sitagliptin 100 mg (408.08; 213.59, 602.57 and 3.74; 1.57, 5.92) compared to Dapagliflozin 5 mg. In terms of the cardiovascular outcome events, there is a significant difference in the heart failure rehospitalization rate of Dapagliflozin 10 mg (0.45; 0.25, 0.82) and Empagliflozin 10 mg (0.48; 0.28, 0.81) compared to Liraglutide 1.8 mg. Further significant differences are found in the all-cause mortality of Dapagliflozin 10 mg (0.81; 0.66, 0.98) compared to Vildagliptin 50 mg; the cardiovascular death of Albiglutide 30 mg (0.49; 0.28, 0.86) compared to Exenatide 2 mg; and the arrhythmic events of Liraglutide 1.8 mg (0.49; 0.26, 0.90) compared to Empagliflozin 10 mg. The network meta-analysis of SGLT2i, GLP-1RA, and DPP4i as a class of drugs showed that GLP-1RA is superior to SGLT2i in improving LVEF and reducing myocardial infarction/acute coronary syndrome, whereas DPP4i is superior to SGLT2i in improving LVEDV and LVESV.

Conclusions:

GLP-1RA is superior to SGLT2i in improving LVEF and reducing myocardial infarction/acute coronary syndrome, whereas DPP4i is superior to SGLT2i in improving LVEDV and LVESV.Key message What is already known on this topic—It has been confirmed that three new hypoglycemic drugs have a protective effect on the cardiovascular system. Studies have shown that sodium-dependent glucose transporter 2 inhibitors (SGLT2i) can improve cardiovascular outcomes and enhance the quality of life of heart failure patients. Currently, SGLT2i is widely used in the clinical treatment of heart failure, and related studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase inhibitor (DPP4i) also play important roles in the treatment of heart failure. What this study adds—However, there is no relevant research on whether these drugs’ clinical efficacy is dose-dependent. How this study might affect research, practice, or policy—This study included different doses of hypoglycemic drugs and used a network meta-analysis method to comprehensively evaluate the effects of three hypoglycemic drugs on heart function, quality of life, and prognosis in heart failure patients, providing a basis for clinical practice.

项与德谷胰岛素/利拉鲁肽相关的新闻（医药）

2025-02-10

·医药笔记

2024年，中国GLP-1市场规模逼近100亿元

▎Armstrong 2025年2月7日，诺和诺德发布2024年财报，中国市场GLP-1销售额72.5亿元人民币，同比增长19%，市场份额80%；减重GLP-1销售额3亿元，同比增长108%。按照诺和诺德的市场数据，中国GLP-1市场规模90.6亿元左右，加上减重的3亿元，总计93.6亿元，已经非常接近100亿元。诺和诺德在中国GLP-1市场仍然保持垄断地位。减重版司美格鲁肽首年上市实现2亿元销售额，利拉鲁肽减重版下降到1亿元。口服降糖版Rybelsus首年上市销售额5.11亿元，同比增长近300%。值得关注的还有胰岛素市场，诺和诺德增长最强劲的两个产品为Xultophy（德谷胰岛素/利拉鲁肽）销售额14亿元，同比增长251%，Ryzodeg（德谷/门冬）销售额27.82亿元，同比增长44%，反映出中国市场对于复方制剂的偏好，延续了预混胰岛素少打一针的同样偏好。Ryzodeg的核心成人包括GLP-1产品利拉鲁肽，也反映出中国市场GLP-1实际销售额已经超过100亿元人民币。总结替尔泊肽在中国也已经获批上市，2025年信达生物的玛仕度肽也将获批上市，GLP-1赛道的竞争进入双靶点时代，预计中国GLP-1市场格局将进一步发生深刻变化。随着产能瓶颈和供应限制的解除，预计中国GLP-1市场将重新进入高速增长阶段。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；科望医药技术全梳理2.0；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

抗体药物偶联物财报

2025-02-06

·echemi

Novo Nordisk Reports 2024 Earnings with $42.13 Billion Revenue and Impressive Profit Margins

On February 5, Novo Nordisk officially released its annual report for 2024, revealing a remarkable revenue of 29.04 billion Danish kroner (approximately $42.13 billion), representing a 25% increase year-on-year. The operating profit also surged to 12.83 billion Danish kroner (around $18.62 billion), reflecting a 25% growth, while net profit reached 10.10 billion Danish kroner (about $14.65 billion), up 21%. Notably, Novo Nordisk's profit margin (operating profit/sales) stands at an impressive 44.19%, far surpassing many American pharmaceutical giants. Novo Nordisk operates primarily in two business segments: Diabetes and Obesity Care and Rare Diseases. The majority of its revenue comes from the Diabetes and Obesity Care segment, which generated 27.18 billion Danish kroner in sales for 2024, while the Rare Diseases segment contributed only 1.86 billion Danish kroner. The GLP-1 class of drugs has emerged as Novo Nordisk's biggest revenue driver. Rybelsus (oral semaglutide) achieved sales of 23.30 billion Danish kroner (approximately $3.38 billion), while Ozempic (injectable semaglutide) brought in 120.34 billion Danish kroner (around $17.46 billion). The weight-loss version, Wegovy, also performed well with sales of 58.21 billion Danish kroner (about $8.44 billion). The total sales for semaglutide reached $29.28 billion, showcasing its strong performance, although it has not yet dethroned Keytruda as the new king of drugs. In addition to semaglutide, Novo Nordisk's GLP-1 offerings include the previous generation liraglutide, with Victoza (liraglutide for diabetes) and Saxenda (liraglutide for weight loss) generating 5.48 billion Danish kroner (approximately $795 million) and 6.94 billion Danish kroner (around $1.01 billion), respectively. Insulin remains Novo Nordisk's second-largest revenue generator, with total sales of 55.37 billion Danish kroner (approximately $8.03 billion) in 2024, driven by the success of degludec insulin, which saw a 15.3% increase in sales compared to the previous year. The three long-acting insulins—Tresiba (degludec), Xultophy (degludec/liraglutide), and Levemir (detemir)—achieved sales of 9.91 billion, 4.67 billion, and 4.50 billion Danish kroner, respectively. The two premixed insulins, Ryzodeg (degludec/aspart) and NovoMix (premixed aspart), generated revenues of 4.93 billion and 5.86 billion Danish kroner, respectively, with the former showing growth while the latter declined. Rapid-acting insulins, including Fiasp (ultra-rapid aspart) and NovoRapid (aspart), collectively sold 18.52 billion Danish kroner, an increase of approximately 2.6 billion compared to the previous year. Additionally, Novo Nordisk continues to sell second-generation human insulin, which generated 6.97 billion Danish kroner, although this segment saw a year-on-year decline. In the Rare Diseases segment, Novo Nordisk's product pipeline primarily includes clotting factors and growth hormones, with total sales of only 1.86 billion Danish kroner, representing a small portion of overall revenue. Unlike other major international pharmaceutical companies, Novo Nordisk has not pursued large-scale acquisitions and maintains a research and development investment intensity of around 15%. However, the company's sustained high revenue growth demonstrates its efficiency in product development. This efficiency can be attributed to four key factors: a strong focus on diabetes, extensive knowledge accumulation over a century, a commitment to user experience, maximizing market value from existing products, and the development of platform technologies. With advanced fatty acid acylation technology, peptide oral delivery technology, and yeast fermentation technology, Novo Nordisk is well-positioned to maintain its competitive edge in the market.

并购财报上市批准生物类似药

2025-02-05

·药事纵横

诺和诺德2024年财报：司美格鲁肽大卖近300亿美元

2月5日，丹麦诺和诺德公司正式公布了2024年年报。诺和诺德全年营收2904.03亿丹麦克朗（约合421.3亿美元），同比增长25%，营业利润1283.39亿丹麦克朗（约合186.2亿美元），同比增长25%，净利润1009.88亿丹麦克朗(约合146.5亿美元），同比增长21%。值得一提的是，诺和诺德的盈利水平（营业利润/销售额）高达44.19%，让美国哪些创新巨头望尘莫及。诺和诺德旗下有糖尿病与肥胖症护理、罕见病两大业务部门，其中营收主要来自糖尿病与肥胖症护理，2024年的总销售额达2717.64亿丹麦克朗，而罕见病仅为186.39亿丹麦克朗。 GLP-1是诺和诺德最大的“印钞机”，Rybelsus（口服司美格鲁肽）2024年卖出233.01亿丹麦克朗（约合33.80亿美元），Ozempic（注射司美格鲁肽）卖出1203.42亿丹麦克朗（约合174.59亿美元），Wegovy（减肥版司美格鲁肽）也卖出582.06亿丹麦克朗（约合84.44亿美元），司美格鲁肽的合计销售额达292.8亿美元，虽然表现非常抢眼，但并没有取代K药成为新一代药王。除了司美格鲁肽，诺和诺德的GLP-1还包括上一代的利拉鲁肽，Victoza（利拉鲁肽降糖）和Saxenda（利拉鲁肽减肥）也分别卖出54.82亿丹麦克朗（约合7.95亿美元）和69.40亿丹麦克朗（约合10.07亿美元）。胰岛素是诺和诺德第二大“印钞机”，2024年总销售额为553.73亿丹麦克朗（约合80.33亿美元），得益于德古胰岛素的拉动，胰岛素总销售额相比去年同期增长了15.3%。三大长效胰岛素 Tresiba（德古胰岛素）、Xultophy（德古胰岛素/利拉鲁肽）和Levemir（地特胰岛素）分别卖出99.05亿丹麦克朗、46.68亿丹麦克朗和45.03亿丹麦克朗。两大预混胰岛素Ryzodeg（德古胰岛素/门冬胰岛素）和NovoMix（预混门冬胰岛素/精蛋白门冬胰岛素）的营收分别为49.29亿丹麦克朗和58.60亿丹麦克朗，业绩表现为前者升后者降。速效胰岛素方面，两大产品 Fiasp（超速效门冬胰岛素配方）和NovoRapid（门冬胰岛素）合计卖出185.22亿丹麦克朗，相比去年同期增加约26亿丹麦克朗。除了以上三代胰岛素，诺和诺德仍在销售二代人胰岛素，其销售额为69.67亿丹麦克朗，销售规模也出现了同比下跌。罕见病方面，诺和诺德的产品管线主要为凝血因子、生长激素等产品，全年营收仅为186.39亿丹麦克朗，在总销售额中的占比非常小，诺和诺德的产品销售额如下表所示：相比其他国际制药巨头，诺和诺德并未开展大规模并购，研发投入强度也仅维持在15%左右，但销售额的持续高速增长充分体现了该公司在产品开发方面的高效性。而这种高效性可以归结于四个方面：一是高度专注于糖尿病，上百年的知识积累，让诺和诺德对疾病有了深刻的理解，让专注变成了专长；二是重视用户体验，不做第一，只做最好，总结整个发展史，诺和诺德并没有推出过首创性（first-in-class）新药，但其推出的都是同领域最好、最便捷的产品，这或许与两家公司相互竞争时形成的文化有关；三是充分利用好手上的产品，让市场价值最大化，最具代表的案例就是利拉鲁肽，诺和诺德不仅开发了减肥针，与胰岛素做成了复方，还积极开展了大量临床试验，证明了产品除降糖外，还具有心血管获益、肾脏功能获益的优势，大大增强了产品的市场竞争力；四是重视平台技术的发展，因为拥有先进的脂肪酸酰化技术、多肽口服技术和酵母菌发酵技术，诺和诺德才具有足够的优势去赢得市场。药事纵横征稿启事

财报并购

100 项与德谷胰岛素/利拉鲁肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A10AE56	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	欧盟	Novo Nordisk A/S	2014-09-18
2型糖尿病	冰岛	Novo Nordisk A/S	2014-09-18
2型糖尿病	列支敦士登	Novo Nordisk A/S	2014-09-18
2型糖尿病	挪威	Novo Nordisk A/S	2014-09-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病	临床1期	德国	Novo Nordisk A/S	2009-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05324462 (SPIRIT, Pubmed) 人工标引	N/A	2型糖尿病	175	IDegLira	醖積製鏇齋製觸築構觸(廠廠觸繭願糧襯觸夢繭) = 遞選鏇網糧鹽衊築廠糧觸鹽繭鹽選選鬱餘範鬱 (淵顧鏇製糧構顧齋鬱糧, - 1.6 ~ - 1.0) 更多	积极	2024-05-08
NCT03737240 (CTgov)	临床3期	2型糖尿病	145	IDegLira (IDegLira)	鏇網鬱顧簾積範糧鑰艱(淵衊簾鬱膚構遞膚夢簾) = 繭簾範獵獵壓願衊鬱願鑰醖鑰醖鹽鑰顧餘遞選 (窪淵膚築衊積積餘範鬱, 2.29) 更多	-	2023-09-08
				Insulin Degludec (U-100)+Insulin Aspart (Basal-Bolus Insulin)	鏇網鬱顧簾積範糧鑰艱(淵衊簾鬱膚構遞膚夢簾) = 憲繭衊夢遞襯獵壓齋鏇鑰醖鑰醖鹽鑰顧餘遞選 (窪淵膚築衊積積餘範鬱, 1.79) 更多
EASD2022	N/A	2型糖尿病 HbA1c \| c-peptide	73	Human BBT	壓鹽築網鹽遞淵製範製(夢糧願遞築遞範糧範構) = 10 (18%) patients reported at least one episode and 6 (10%) patients had more than one episode of mild hypoglycemia 糧積鏇築壓淵憲觸襯顧 (齋膚遞願鏇鏇膚壓膚顧 )	积极	2022-09-20
				IDegLira
IDegLira-HIGH Trial (ADA2022)	N/A	2型糖尿病	-	IDegLira	鬱鑰蓋壓鑰製膚齋齋範(願鏇選製襯淵鏇獵願簾) = 憲遞鹽鹹製範觸醖網願蓋衊齋遞壓糧糧簾憲壓 (淵觸願鹽襯窪膚積觸觸 ) 更多	积极	2022-06-01
				Basal Bolus	鬱鑰蓋壓鑰製膚齋齋範(願鏇選製襯淵鏇獵願簾) = 膚鑰積簾鬱範簾積衊淵蓋衊齋遞壓糧糧簾憲壓 (淵觸願鹽襯窪膚積觸觸 ) 更多
NCT03172494 (DUAL I China, EASD2020)	临床3期	2型糖尿病	720	IDegLira	齋餘壓構鏇鬱膚艱壓顧(襯壓鹽膚鑰衊構醖顧築): ETD = -0.59 (95% CI, -0.73 ~ -0.46) 更多	积极	2020-09-23
				IDeg
NCT03175120 (DUAL II China, EASD2020)	临床3期	2型糖尿病	453	IDegLira	鹹衊積願築淵齋鬱選範(範齋鑰艱鑰衊糧鬱淵鹹): P-Value = <0.0001 更多	积极	2020-09-23
				Insulin degludec
NCT03172494 (DUAL I China \| DUAL™ I China, CTgov)	临床3期	2型糖尿病	720	Insulin degludec/liraglutide (Insulin Degludec/Liraglutide)	簾鹹衊選艱蓋鑰積獵醖(積夢遞憲糧夢鑰顧膚蓋) = 鹽艱鬱膚積壓築簾鏇鏇膚醖範製構憲簾觸蓋觸 (餘壓獵鹽齋鬱壓鑰壓製, 0.88) 更多	-	2020-07-07
				Insulin degludec (Insulin Degludec)	簾鹹衊選艱蓋鑰積獵醖(積夢遞憲糧夢鑰顧膚蓋) = 齋願餘積獵鏇構遞鏇夢膚醖範製構憲簾觸蓋觸 (餘壓獵鹽齋鬱壓鑰壓製, 0.99) 更多
NCT03175120 (DUAL™ II China \| DUAL II China, CTgov)	临床3期	2型糖尿病	453	Insulin degludec/liraglutide (Insulin Degludec/Liraglutide)	獵廠範積蓋鏇糧範觸襯(齋憲廠觸膚衊糧範鬱積) = 鬱艱繭築選憲範窪積鹹選鏇醖齋鏇選願糧範獵 (網繭蓋艱製觸廠窪淵選, 1.14) 更多	-	2020-03-19
				Insulin degludec (Insulin Degludec)	獵廠範積蓋鏇糧範觸襯(齋憲廠觸膚衊糧範鬱積) = 簾憲顧淵簾鏇網淵簾廠選鏇醖齋鏇選願糧範獵 (網繭蓋艱製觸廠窪淵選, 1.19) 更多
NCT02420262 \| NCT01952145 (Pubmed \| Diabet Med)	临床3期	2型糖尿病	-	Insulin degludec/liraglutide (IDegLira)	鏇鹽壓齋夢鏇鬱鏇蓋壓(鹽鏇憲願淵窪鹽網餘願) = 憲廠餘鬱繭糧餘簾鬱糧觸網廠鏇遞鑰簾醖選積 (衊顧餘鑰範顧積範鬱積 ) 更多	-	2020-02-01
NCT02911948 (Pubmed \| Diabetes Obes Metab) 人工标引	临床3期	2型糖尿病	210	metformin+degludec/liraglutide	餘製鬱糧艱淵糧襯積鹹(鏇繭遞鑰鏇廠獵糧窪糧): ETD = -13.98 (95% CI, -16.41 ~ -11.55), P-Value = <0.0001 更多	优效	2019-12-01
				metformin+degludec